News | June 28, 2007

FDA Clears St. Jude Medical's QuickOpt Timing Cycle

June 29, 2007 – St. Jude Medical, Inc. today announced that the FDA and European CE Mark approvals to expand the capabilities of its Frontier II cardiac resynchronization therapy pacemaker (CRT-P) to include QuickOpt Timing Cycle Optimization, designed to provide physicians a new option to manage therapy for patients based on their individual needs.
The Frontier II device is the first heart failure pacemaker with QuickOpt Timing Cycle Optimization. In about 90 seconds, the QuickOpt feature recommends to physicians which A-V (atrial-ventricular) and V-V (ventricular-ventricular) timing values to use to program the devices. This allows physicians to frequently optimize devices as their patients’ needs change over time.
Because heart disease is different for each patient, customizing device settings for each patient – called “optimization” – enhances device performance so that it works in the most efficient manner possible. However, few patients currently receive the full benefit of their devices because echocardiography – the current gold standard – can be expensive and time-consuming.
QuickOpt Optimization produces results clinically-proven to be comparable to echocardiography, but is significantly less costly and time-consuming. A typical echo procedure takes between 30 and 120 minutes and requires interpretation by a technician, whereas QuickOpt Optimization is performed during patients' regularly scheduled follow-up visits in about 90 seconds.

For more information: www.sjm.com

Related Content

Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Sponsored Content | Videos | Cardiovascular Ultrasound| June 29, 2017
Leyla Elif Sade, M.D., MESC, professor of cardiology at Başkent University, Ankara, Turkey, discusses use of echo for
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Overlay Init